According to a new research in Gastroenterology.

Adalimumab effective in maintaining remission in pediatric patients with Crohn’s disease Adalimumab works well in maintaining remission using pediatric sufferers with Crohn’s disease, according to a new research in Gastroenterology, the state journal of the American Gastroenterological Association . Steroids are generally used in Crohn’s disease, but may stunt delay and growth puberty. Incidence of this disease, which causes intestinal swelling, is on the rise in children. This study may be the largest double-blind research of an anti-TNF agent in kids with Crohn’s disease.

Masao Suzuki, L.Ac., Ph.D., of Kyoto University and Meiji University of Integrative Medicine, Kyoto, Japan, from July 2006 through March 2009 and colleagues conducted a randomized controlled trial. A complete of 68 patients diagnosed with COPD participated, and 34 were assigned to a genuine acupuncture group for 12 weeks, plus daily medicine. The other 34 were assigned to a placebo acupuncture group where the needles had been blunt . The principal measure was the evaluation of a six-minute walk test on a Borg scale where 0 meant ‘breathing very well, barely breathless’ and 10 signified ‘severely breathless.’ Related StoriesCamels in Kenya infected by MERS virus, brand-new study findsCareFusion to show fresh respiratory solutions at AARC CongressNew vaccine candidate shows great promise at fighting respiratory syncytial virus’We demonstrated clinically relevant improvements in DOE [dyspnea on exertion] , nutrition position , airflow obstruction, exercise capability and health-related quality of life after 90 days of acupuncture treatment,’ the authors note.